公开(公告)号：WO2008127094A3

公开(公告)日：2009-01-15

申请号：PCT/NL2008050191

申请日：2008-04-07

Applicant: STICHTING KATHOLIEKE UNIV ,  HERMANS PETER WILHELMUS MARIA ,  BOOTSMA HESTER JEANETTE ,  BURGHOUT PIETER JAN ,  BIJLSMA JOHANNA JACOBA ELISABE ,  KUIPERS OSCAR PAUL ,  KLOOSTERMAN TOMAS GERRIT

Inventor： HERMANS PETER WILHELMUS MARIA ,  BOOTSMA HESTER JEANETTE ,  BURGHOUT PIETER JAN ,  BIJLSMA JOHANNA JACOBA ELISABETH ,  KUIPERS OSCAR PAUL ,  KLOOSTERMAN TOMAS GERRIT

IPC: A61K39/09

CPC classification number: A61K39/092 ,  A61K9/0019 ,  A61K9/107 ,  A61K39/09 ,  A61K47/22 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55594

Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.

Abstract translation: 本发明提供蛋白质/基因，其对于存活是必不可少的，因此提供了肺炎链球菌在体内的毒力，因此是针对肺炎球菌感染的疫苗制剂的理想疫苗候选物。 此外，本发明还包括针对所述蛋白质的抗体。

公开(公告)号：WO2007071454A2

公开(公告)日：2007-06-28

申请号：PCT/EP2006012536

申请日：2006-12-27

Applicant: STICHTING KATHOLIEKE UNIV ,  ADEMA GOSSE JAN ,  TRIANTIS VASSILIS ,  FIGDOR CARL GUSTAV ,  ANSEMS MARLEEN

Inventor： ADEMA GOSSE JAN ,  TRIANTIS VASSILIS ,  FIGDOR CARL GUSTAV ,  ANSEMS MARLEEN

IPC: A61K48/00

CPC classification number: C07K14/4702

Abstract: The present invention relates to isolated nucleic acid molecule encoding the transcription regulator DC- SCRIPT or a derivative thereof . The invention further relates to its use in therapy and to compound for interfering with the biological function of the transcription factor DC-SCRIPT. Such compounds can be compounds interfering with expression of DC-SCRIPT; or compounds interfering with binding of DC- SCRIPT to DNA.

Abstract translation: 本发明涉及编码转录调节物DC-SCRIPT的分离的核酸分子或其衍生物。 本发明还涉及其在治疗中的用途和用于干扰转录因子DC-SCRIPT的生物学功能的化合物。 这些化合物可以是干扰DC-SCRIPT表达的化合物; 或干扰DC-SCRIPT与DNA结合的化合物。

公开(公告)号：WO2007016938A3

公开(公告)日：2007-05-10

申请号：PCT/EP2005008322

申请日：2005-07-27

Applicant: STICHTING KATHOLIEKE UNIV ,  TJALSMA HAROLD

Inventor： TJALSMA HAROLD

IPC: G01N33/574 ,  C07K14/315

CPC classification number: G01N33/57419 ,  A61K39/00 ,  C07K14/315 ,  G01N2333/315 ,  G01N2469/20

Abstract: The present invention relates to methods for diagnosing colon cancer in an individual, especially the diagnosis of an pre or early stage of colon cancer, comprising detecting the presence of immunoglobulin molecules directed against Streptococcus bovis antigens in a sample of the individual comprising total serum immunoglobulin molecules. The present invention further relates to antigens for use in said method and to the use of the antigens as a diagnosticum and/or medicament. Preferred antigens are HlpA and RpL7/L12. The most preferred detection method involves capturing the S. Bovis antigens on a solid support, to which the immunoglobulin analytes have been previously immobilized.

Abstract translation: 本发明涉及用于诊断个体中结肠癌的方法，特别是结肠癌的早期或早期阶段的诊断方法，包括检测针对牛链球菌抗原的免疫球蛋白分子的存在，所述免疫球蛋白分子包含总血清免疫球蛋白分子 。 本发明还涉及用于所述方法的抗原和抗原作为诊断和/或药物的用途。 优选的抗原是HlpA和RpL7 / L12。 最优选的检测方法包括在固体支持物上捕获S.Bovis抗原，免疫球蛋白分析物先前已经被固定在其上。

公开(公告)号：WO2004026909A2

公开(公告)日：2004-04-01

申请号：PCT/IB0305181

申请日：2003-09-19

Applicant: STICHTING KATHOLIEKE UNIV ,  FIGDOR CARL GUSTAV ,  TORENSMA RUURD ,  VAN LENT PETRUS LEONARDUS EVER ,  VAN DEN BERG WIM B

Inventor： FIGDOR CARL GUSTAV ,  TORENSMA RUURD ,  VAN LENT PETRUS LEONARDUS EVER ,  VAN DEN BERG WIM B

IPC: A61K31/7004 ,  A61K38/16 ,  A61P19/02 ,  C07K16/28 ,  G01N33/564 ,  C07K16/00

CPC classification number: A61K31/70 ,  A61K31/7004 ,  A61K38/162 ,  A61K38/168 ,  A61K2039/505 ,  C07K16/2851 ,  C07K16/2896 ,  G01N33/564 ,  G01N2800/102

Abstract: The C-type lectin DC-SIGN is absent in normal synovium but is highly expressed by CD68 positive macrophages in the synovium of rheumatoid arthritis patients. Accordingly, rheumatoid arthritis is diagnosed or treated by, respectively, assaying or blocking DC-SIGN. This can be accomplished by the use of agents, e.g., antibodies, which bind specifically to DCSIGN. Agents that bind to ICAM-3 are used to block inhibition of activation of macrophages by DC-SIGN-ICAM-3 interaction and cause inhibition of rheumatoid arthritis symptoms.

Abstract translation: C型凝集素DC-SIGN在正常滑膜中不存在，但在类风湿关节炎患者滑膜中的CD68阳性巨噬细胞高度表达。 因此，通过分别诊断或阻断DC-SIGN来诊断或治疗类风湿性关节炎。 这可以通过使用特异性结合DCSIGN的试剂，例如抗体来实现。 结合ICAM-3的药物用于阻断DC-SIGN-ICAM-3相互作用对巨噬细胞活化的抑制，并引起对类风湿关节炎症状的抑制。

公开(公告)号：WO2016071431A9

公开(公告)日：2016-11-03

申请号：PCT/EP2015075778

申请日：2015-11-05

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： ADEMA GOSSE JAN ,  BÜLL CHRISTIAN ,  BOLTJE THOMAS JAN

IPC: A61K39/39 ,  A61K31/351 ,  A61K31/7088 ,  C12N15/117

CPC classification number: A61K39/39 ,  A61K31/7024 ,  A61K31/7088 ,  A61K45/06 ,  C12N15/117 ,  C12N2310/17 ,  C12N2320/31 ,  A61K2300/00

Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to a novel combination for use in the treatment, prevention and/or delay of cancer.

Abstract translation: 本发明涉及医学和免疫学领域。 特别涉及用于治疗，预防和/或延缓癌症的新型组合。

公开(公告)号：WO2012169887A3

公开(公告)日：2013-03-14

申请号：PCT/NL2012050394

申请日：2012-06-06

Applicant: STICHTING KATHOLIEKE UNIV ,  HERMANS PETER WILHELMUS MARIA ,  DE GROOT RONALD ,  FERWERDA JACOB GERBEN

Inventor： HERMANS PETER WILHELMUS MARIA ,  DE GROOT RONALD ,  FERWERDA JACOB GERBEN

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158

Abstract: The invention comprises a method for the prediction of the severity of a disease developing from an infection with human respiratory syncytial virus (RSV) in a subject, comprising detection of overexpression of OLFM4, CD177, MMP8, MMP9, PTX3 or a combination of one or more of these with one or more chosen from the group of IL8, RANTES and CD4 count. The overexpression can be detected in a blood sample by a nucleic acid assay or through an immunoassay.

Abstract translation: 本发明包括用于预测受试者中由人呼吸道合胞病毒（RSV）感染发展的疾病的严重性的方法，其包括检测OLFM4，CD177，MMP8，MMP9，PTX3的过表达或其中一种或多种 其中更多的是选自IL8，RANTES和CD4计数的一种或多种。 可以通过核酸测定或通过免疫测定在血液样品中检测到过表达。

公开(公告)号：WO2011007012A1

公开(公告)日：2011-01-20

申请号：PCT/EP2010060373

申请日：2010-07-16

Applicant: STICHTING KATHOLIEKE UNIV ,  ROWAN ALAN EDWARD ,  NOLTE ROELAND JOHANNES MARIA ,  CORNELISSEN JEROEN JOHANNES LAMBERTUS MARIA ,  KITTO HEATHER JOY ,  SCHWARTZ ERIK ,  KOEPF MATTHIEU

Inventor： ROWAN ALAN EDWARD ,  NOLTE ROELAND JOHANNES MARIA ,  CORNELISSEN JEROEN JOHANNES LAMBERTUS MARIA ,  KITTO HEATHER JOY ,  SCHWARTZ ERIK ,  KOEPF MATTHIEU

IPC: C08G18/09 ,  C08G18/50

CPC classification number: C08G69/40 ,  C08G65/33348 ,  C08L77/04 ,  C08L2201/54 ,  C09D177/04

Abstract: The present invention relates to a process for the preparation of oligo(alkylene glycol) functionalized polyisocyanopeptides comprising the steps of functionalizing an isocyanopeptide with oligo-(alkylene glycol) side chains and subsequently polymerizing the oligo-alkylene glycol functionalized isocyanopeptides. Several isocyanopeptide may be functionalized with various linear or non-linear oligo-(alkylene glycol) side chains having variable chain length. The alkylene glycol may be selected from the group consisting of ethylene-, propylene-, butylene- or pentylene glycol. Preferably the isocyanopeptides are functionalized with at least 3 ethylene glycol side chains. The peptides may comprise L aminoacids, D-aminoacids or D, L-aminoacids. The obtained oligoalkylene functionalized polyisocyanopeptides are a new class of materials with unique thermo-responsive properties.

Abstract translation: 本发明涉及制备寡（亚烷基二醇）官能化聚异氰肽的方法，其包括用寡聚（亚烷基二醇）侧链官能化异氰肽并随后聚合寡聚亚烷基二醇官能化异氰肽的步骤。 几种异氰肽可以用具有可变链长的各种线性或非线性低聚（亚烷基二醇）侧链官能化。 亚烷基二醇可以选自乙烯 - ，丙烯 - ，丁烯 - 或戊二醇。 优选地，异氰肽用至少3个乙二醇侧链官能化。 肽可以包含L个氨基酸，D-氨基酸或D，L-氨基酸。 获得的低聚亚烷基官能化的聚异氰肽是一类具有独特的热响应性质的新型材料。

公开(公告)号：WO2008075955A3

公开(公告)日：2008-09-12

申请号：PCT/NL2007050676

申请日：2007-12-20

Applicant: STICHTING TECH WETENSCHAPP ,  STICHTING KATHOLIEKE UNIV ,  RUTJES FLORIS PETRUS JOHANNES ,  CORNELISSEN JEROEN JOHANNES LA ,  VAN BERKEL SANDER SEBASTIAAN ,  DIRKS ANTONIUS JOHANNES

Inventor： RUTJES FLORIS PETRUS JOHANNES ,  CORNELISSEN JEROEN JOHANNES L ,  VAN BERKEL SANDER SEBASTIAAN ,  DIRKS ANTONIUS JOHANNES

IPC: C07D249/04 ,  C07D487/08 ,  C07D493/08

CPC classification number: C07D249/04 ,  C07D487/08 ,  C07D493/08

Abstract: The present invention relates to a process for the preparation of 1,4,5- trisubstituted triazoles and 3,4,5-trisubstituted triazoles according to Formulas (Ia) and 5 (Ib), and mesomers and tautomers thereof, wherein a compound according to Formula (II) or Formula (III): is reacted with a compound according to Formula (IV). The process is very useful for the selective and site-specific addition of azide compounds to optionally activated alkynes to form 1,4,5-trisubstuted triazoles and mesomers and tautomers thereof and the application of this process to the covalent functionalisation of biomolecules.

Abstract translation: 本发明涉及制备根据式（Ia）和5（Ib）的1,4,5-三取代三唑和3,4,5-三取代三唑及其互变异构体和互变异构体的方法， 与式（II）或式（III）反应：与式（IV）化合物反应。 该方法对于将选择性和位点特异性加成任选活化的炔烃以形成1,4,5-三分子三唑及其互变异构体和互变异构体以及将该方法应用于生物分子的共价官能化是非常有用的。

公开(公告)号：WO2004026326A3

公开(公告)日：2004-05-21

申请号：PCT/IB0304661

申请日：2003-09-19

Applicant: STICHTING KATHOLIEKE UNIV ,  FIGDOR CARL GUSTAV ,  TORENSMA RUURD

Inventor： FIGDOR CARL GUSTAV ,  TORENSMA RUURD

IPC: A61K31/702 ,  A61K38/17 ,  A61P31/00 ,  C07K16/28 ,  A61K38/08 ,  A61K39/395

CPC classification number: A61K38/08 ,  A61K31/702 ,  A61K38/1774 ,  A61K2039/505 ,  C07K16/2851 ,  C07K2317/34 ,  C07K2317/76

Abstract: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candida albicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind Candida albicans both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize Candida in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another Candida receptor on DC. Together, these results demonstrate that C. albicans has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.

Abstract translation: 表达II型C型凝集素DC-SIGN（CD209）的树突状细胞（DC）位于组织粘膜下层，其中介导HIV-1进入。 有趣的是，病原体白色念珠菌是医院获得性真菌感染的主要原因，发现于相似的部位。 这证明DC-SIGN能够在DC-SIGN转染的细胞系和人单核细胞衍生的DC中结合白色念珠菌。 此外，在未成熟的DC中，DC-SIGN能够将念珠菌内含于特异性DC-SIGN富集的囊泡中，与含有甘露糖受体（MR; CD206）的那些不同，这是DC上的另一种念珠菌受体。 这些结果一起证明白色念珠菌在人单核细胞衍生的DC上具有两个主要受体，这些受体是DC-SIGN和MR。 针对DC-SIGN提供了新的机会来抵抗慢性念珠菌病。

公开(公告)号：WO2016114662A3

公开(公告)日：2016-09-22

申请号：PCT/NL2016050030

申请日：2016-01-13

Applicant: STICHTING KATHOLIEKE UNIV

Inventor： VAN HEERDE WAANDER LAURENS

IPC: C12Q1/68 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  G01N33/6893 ,  G01N2333/4718 ,  G01N2405/00 ,  G01N2800/222 ,  G01N2800/50

Abstract: The present disclosure relates to an in vitro method for determining Von Willebrand Disease or an increased risk of developing Von Willebrand Disease. The method involves determining whether a point mutation at a defined position is present or absent in the ANXA2 gene sequence. Also disclosed is a kit for determining Von Willebrand Disease or an increased risk of developing Von Willebrand Disease comprising means for determining the point mutation.

Abstract translation: 本公开涉及确定冯维勒布兰德氏病或增加发展冯维勒布兰德氏病风险的体外方法。 该方法涉及确定ANXA2基因序列中确定位置的点突变是否存在或不存在。 还公开了用于确定冯维勒布兰德氏病或增加发生冯维勒布兰德氏病的风险的试剂盒，其包含用于确定点突变的手段。